Claims for Patent: 5,914,122

Summary for Patent: 5,914,122

Title:	Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams
Abstract:	A stable budesonide solution with a pH not exceeding 6.0 in which the budesonide is dissolved in a solvent which may be water, an alcohol such as ethanol, isopropanol or propylene glycol, or a water/alcohol mixture. The solution preferably also contains a stabilizer such as sodium ethylenediaminetetraacetic acid, cyclodextrins or mixtures thereof. The stable budesonide solution is useful as the active ingredient in a rectal enema or a rectal foam.
Inventor(s):	Otterbeck; Norbert (Uberlingen, DE), Kuhn; Reimund (Freiamt, DE)
Assignee:	Dr. Falk Pharma GmbH (Freiburg, DE)
Application Number:	08/860,136
Patent Claims:	1. A stable budesonide solution with a pH not exceeding 6.0 in which the budesonide is dissolved in a solvent selected from the group consisting of water, alcohol and a water/alcohol mixture and wherein the alcohol is selected from the group consisting of ethanol, isopropanol and propylene glycol. 2. A stable budesonide solution as in claim 1, which comprises a stabilizing additive selected from the group consisting of sodium ethylenediaminetetraacetic acid, cyclodextrins and mixtures thereof. 3. A stable budesonide solution with a pH not exceeding 6.0 in which the budesonide is dissolved in a solvent selected from the group consisting of water, alcohol and a water/alcohol mixture and wherein the alcohol is selected from the group consisting of ethanol, isopropanol and propylene glycol, which comprises 0.001 to 0.1% by weight of budesonide. 4. A stable budesonide solution with a pH not exceeding 6.0 in which the budesonide is dissolved in a solvent selected from the group consisting of water, alcohol and a water/alcohol mixture and wherein the alcohol is selected from the group consisting of ethanol, isopropanol and propylene glycol, further comprising 0.05 to 1.0% by weight of cyclodextrins. 5. A stable budesonide solution as in claim 1, with a pH not exceeding 6.0 comprising 0.001 to 0.1% by weight of budesonide and stabilizing additives selected from the group consisting of 0.001 to 0.1% by weight of sodium ethylenediaminetetraacetic acid; 0.05 to 1.0% by weight of cyclodextrins and a mixture of said amounts of sodium ethylenediaminetetraacetic acid and cyclodextrins. 6. A process for producing a stable budesonide-containing solution with a pH not exceeding 6.0 which comprises dissolving the budesonide in a solvent selected from the group consisting of water, alcohol and a water/alcohol mixture, with the alcohol selected from the group consisting of ethanol, isopropanol and propylene glycol, and adjusting the pH of the budesonide solution to a value not exceeding 6.0. 7. A process as in claim 6, which comprises adding thereto a stabilizing additive selected from the group consisting of sodium ethylenediaminetetraacetic, cyclodextrins and a mixture thereof. 8. A process as in claim 6, wherein the solution comprises 0.001 to 1% by weight of budesonide and the stabilizing additive is selected from the group consisting of 0.001 to 1% by weight of sodium ethylenediaminetetraacetic acid, 0.05 to 1.0% by weight of cyclodextrins and a mixture of said amounts of sodium ethylenediaminetetraaceticacetic acid and cyclodextrins. 9. An enema solution which comprises as the active ingredient, a stable budesonide solution as in claim 1. 10. An enema solution which comprises as the active ingredient, a stable budesonide solution as in claim 2. 11. An enema solution which comprises as the active ingredient, a stable budesonide solution as in claim 3. 12. An enema solution which comprises as the active ingredient, a stable budesonide solution as in claim 4. 13. An enema solution which comprises as the active ingredient, a stable budesonide solution as in claim 5. 14. An enema solution which comprises as the active ingredient, stable budesonide solution as in claim 6. 15. A rectal foam which comprises, as the active ingredient, a stable aqueous budesonide solution as in claim 1. 16. A rectal foam which comprises as the active ingredient, a stable budesonide solution as in claim 2. 17. A rectal foam which comprises as the active ingredient, a stable budesonide solution as in claim 3. 18. A rectal foam which comprises as the active ingredient, a stable budesonide solution as in claim 4. 19. A rectal foam which comprises as the active ingredient, a stable budesonide solution as in claim 5. 20. A rectal foam which comprises as the active ingredient, a stable budesonide solution as in claim 6. 21. A stable budesonide solution with a pH not exceeding 6.0 in which the budesonide is dissolved in a solvent selected from the group consisting of water, alcohol and a water/alcohol mixture and wherein the alcohol is selected from the group consisting of ethanol, isopropanol and propylene glycol, further comprising 0.001 to 0.1% by weight of sodium ethylenediaminetetraacetic acid. 22. A stable budesonide solution with a pH not exceeding 6.0 in which the budesonide is dissolved in a solvent selected from the group consisting of water, alcohol and a water/alcohol mixture and wherein the alcohol is selected from the group consisting of ethanol, isopropanol and propylene glycol, comprising 0.001 to 0.1% by weight of budesonide and stabilizing additives selected from the group consisting of 0.001 to 0.1% by weight of sodium ethylene-diaminetetraacetic acid, 0.05 to 1.0% by weight of cyclodextrins and a mixture of said amounts of sodium ethylene-diaminetetraacetic acid and cyclodextrins.